1. Home
  2. BIRD vs SCYX Comparison

BIRD vs SCYX Comparison

Compare BIRD & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Allbirds Inc.

BIRD

Allbirds Inc.

HOLD

Current Price

$3.20

Market Cap

28.8M

ML Signal

HOLD

Logo SCYNEXIS Inc.

SCYX

SCYNEXIS Inc.

HOLD

Current Price

$0.87

Market Cap

32.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BIRD
SCYX
Founded
2015
1999
Country
United States
United States
Employees
N/A
N/A
Industry
Apparel
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
28.8M
32.6M
IPO Year
2021
2014

Fundamental Metrics

Financial Performance
Metric
BIRD
SCYX
Price
$3.20
$0.87
Analyst Decision
Buy
Strong Buy
Analyst Count
2
1
Target Price
$11.00
$3.00
AVG Volume (30 Days)
73.7K
328.6K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
61.36
EPS
N/A
N/A
Revenue
$189,757,000.00
$257,000.00
Revenue This Year
N/A
$90.24
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.45
$0.57
52 Week High
$12.84
$1.29

Technical Indicators

Market Signals
Indicator
BIRD
SCYX
Relative Strength Index (RSI) 48.53 62.21
Support Level $2.45 $0.69
Resistance Level $3.36 $0.88
Average True Range (ATR) 0.33 0.06
MACD 0.08 0.01
Stochastic Oscillator 44.59 72.97

Price Performance

Historical Comparison
BIRD
SCYX

About BIRD Allbirds Inc.

Allbirds Inc is a lifestyle brand that innovates with naturally derived materials to make footwear and apparel products in a better way, while treading lighter on the planet. Its primary source of revenue is from sales of shoes and apparel products. The majority of the revenue is derived from United States.

About SCYX SCYNEXIS Inc.

SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.

Share on Social Networks: